Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01998126
Recruitment Status : Completed
First Posted : November 28, 2013
Last Update Posted : April 2, 2018
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
University of Utah

Brief Summary:

The goals of the overall study are to evaluate a recommended phase 2 dose and the short and long term toxicities of the combinations. This is a modified phase I trial of immune checkpoint inhibitors in combination with mutation - specific targeted therapy (crizotinib or erlotinib) at conventional doses stratified for presence of ALK (Anaplastic lymphoma kinase) or EGFR (epidermal growth factor receptor) mutation.

The goals of the overall study are to evaluate a recommended phase 2 dose and the short and long term toxicities of the combinations.


Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Drug: Ipilimumab Drug: Erlotinib Drug: Crizotinib Drug: Nivolumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Combination Checkpoint Inhibitor Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts
Actual Study Start Date : December 2, 2013
Actual Primary Completion Date : May 9, 2017
Actual Study Completion Date : March 29, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: EGFR patients with ipilimumab
ipilimumab and erlotinib in EGFR mutated patients
Drug: Ipilimumab
Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)
Other Name: Yervoy

Drug: Erlotinib
Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)

Experimental: ALK patients plus ipilimumab
ipilimumab and crizotinib in ALK mutated patients
Drug: Ipilimumab
Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)
Other Name: Yervoy

Drug: Crizotinib
Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)

Experimental: EGFR patients with nivolumab
nivolumab and erlotinib in EGFR mutated patients
Drug: Erlotinib
Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)

Drug: Nivolumab
Other Name: Nivolumab 240 mg every 2 weeks

Experimental: ALK patients plus nivolumab
nivolumab and crizotinib in ALK mutated patients
Drug: Crizotinib
Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)

Drug: Nivolumab
Other Name: Nivolumab 240 mg every 2 weeks




Primary Outcome Measures :
  1. toxicity of ipilimumab and erlotinib in EGFR mutated patients [ Time Frame: 36 months ]
    The immune-related response criteria (irRC) incorporate several elements reflecting the complex tumor dynamics of ipilimumab/nivolumab treatment. Under these criteria, a measure of tumor volume is used that incorporates the contribution of new measurable lesions. Each net percentage change in tumor burden per assessment using irRC accounts for the size and growth kinetics of both old and new lesions as they appear. New lesions alone do not qualify as immune-related progressive disease.

  2. toxicity of ipilimumab and crizotinib in ALK mutated patients [ Time Frame: 36 months ]
    The immune-related response criteria (irRC) incorporate several elements reflecting the complex tumor dynamics of ipilimumab/nivolumab treatment. Under these criteria, a measure of tumor volume is used that incorporates the contribution of new measurable lesions. Each net percentage change in tumor burden per assessment using irRC accounts for the size and growth kinetics of both old and new lesions as they appear. New lesions alone do not qualify as immune-related progressive disease.

  3. toxicity of nivolumab and erlotinib in EGFR mutated patients [ Time Frame: 36 months ]
    The immune-related response criteria (irRC) incorporate several elements reflecting the complex tumor dynamics of ipilimumab/nivolumab treatment. Under these criteria, a measure of tumor volume is used that incorporates the contribution of new measurable lesions. Each net percentage change in tumor burden per assessment using irRC accounts for the size and growth kinetics of both old and new lesions as they appear. New lesions alone do not qualify as immune-related progressive disease.

  4. toxicity of nivolumab and crizotinib in ALK mutated patients [ Time Frame: 36 months ]
    The immune-related response criteria (irRC) incorporate several elements reflecting the complex tumor dynamics of ipilimumab/nivolumab treatment. Under these criteria, a measure of tumor volume is used that incorporates the contribution of new measurable lesions. Each net percentage change in tumor burden per assessment using irRC accounts for the size and growth kinetics of both old and new lesions as they appear. New lesions alone do not qualify as immune-related progressive disease.


Secondary Outcome Measures :
  1. Response rate [ Time Frame: 36 months ]
  2. Progression Free Survival (PFS) [ Time Frame: 36 months ]
  3. Overall Survival [ Time Frame: 36 months ]
  4. immune function pre and post immune therapy [ Time Frame: 36 months ]

    The immune-related response criteria (irRC) incorporate several elements reflecting the complex tumor dynamics of ipilimumab treatment. Under these criteria, a measure of tumor volume is used that incorporates the contribution of new measurable lesions. Each net percentage change in tumor burden per assessment using irRC accounts for the size and growth kinetics of both old and new lesions as they appear. New lesions alone do not qualify as immune-related progressive disease.

    In this study, immune-related response criteria (irRC) will be used to assess subject response to study treatment per investigator assessment. The secondary endpoint irPFS will be determined based on investigator assessment. In order to adequately address this secondary objective, investigators will follow the clinical practice guidelines to obtain additional tumor assessments beyond mWHO PD and follow the instructions in this section for the determination of immune-related response.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Stage IV Non-Small Cell Lung Cancer (NSCLC), or Stages II - III NSCLC that cannot be treated curatively with standard techniques.
  • Non-Small Cell Lung Cancer (NSCLC) that is either EGFR or ALK mutated.
  • Untreated with/or actively treated with specific inhibitor for less than 6 months if not progressing on active therapy.
  • Age > 18.
  • ECOG performance status 0, 1 or 2.
  • Prior chemotherapy is allowed if > one month from the end of treatment. Patients must not have received chemotherapy within 4 weeks of the start of study drug.
  • Brain metastases are allowed if the patient is asymptomatic or previous steroid treatment was discontinued > 6 weeks.
  • Adequate bone marrow function as defined in the protocol
  • Serum bilirubin levels < 1.5 mg/dL except for patients with Gilbert's syndrome.
  • Adequate organ function as defined in the protocol
  • If female and of childbearing potential, documentation of negative pregnancy test (serum or urine) within 7 days prior to first dose.
  • Able to provide informed consent and have signed an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria:

  • Concurrent therapy with any other non-protocol anti-cancer therapy.
  • History of any other malignancy requiring active treatment.
  • Patients who have had a history of acute diverticulitis, intra-abdominal abscess, Gastrointestical obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation.
  • History of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome). History of vitiligo and adequately controlled endocrine deficiencies such as hypothyroidism are allowed.
  • Significant cardiovascular disease including:

    • Active, clinically symptomatic left ventricular failure.
    • Uncontrolled symptomatic hypertension that cannot be controlled with anti-hypertensive agents.
    • Myocardial infarction, severe angina, or unstable angina within 6 months prior to administration of first dose of study drug.
    • History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation)
    • Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication)
    • Coronary or peripheral artery bypass graft within 6 months of screening.
  • Uncontrolled CNS metastases are not allowed; subjects with previously treated brain metastases will be allowed if the brain metastases have been treated, toxicities have resolved to grade 1 or baseline and steroids are no longer required. Leptomeningeal metastases are not allowed.
  • Serious/active infection or infection requiring parenteral antibiotics.
  • Pregnant or lactating females.
  • HIV infection or chronic hepatitis B or C. Negative Screening tests for HIV, Hepatitis B, and Hepatitis C are required.
  • The presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01998126


Locations
Layout table for location information
United States, Utah
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Sponsors and Collaborators
University of Utah
Bristol-Myers Squibb

Layout table for additonal information
Responsible Party: University of Utah
ClinicalTrials.gov Identifier: NCT01998126     History of Changes
Other Study ID Numbers: HCI66705
First Posted: November 28, 2013    Key Record Dates
Last Update Posted: April 2, 2018
Last Verified: March 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Nivolumab
Ipilimumab
Erlotinib Hydrochloride
Crizotinib
Antineoplastic Agents, Immunological
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action